Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P950020/S148

WOLVERINE Coronary Cutting Balloon

Boston Scientific Corp · Decision date Jan 27, 2026

FDA DECISIONP950020/S148

What did the FDA decide?

FDA records P950020/S148 as a supplement to PMA P950020, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jan 27, 2026.

FDA approval order statement

changes in sponge optimization for catheter coating, DI water spraying interval, and UV upper limits
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Jan 27, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P950020/S148
Regulatory pathway
PMA supplement
Product code
NWX
Decision code
OK30
Decision date
Jan 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Catheter, percutaneous transluminal coronary angioplasty (ptca), cutting/scoring.

Product code
NWX
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P950020/S147 · Related supplement

    WOLVERINE Coronary Cutting Balloon

  2. P950020/S148 received

    Application receipt date recorded by FDA.

  3. P950020/S148 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P950020. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P950020

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA supplementDec 1, 2025FDA

Explore the linked device profile

Other records with product code NWX

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
One Scimed Pl., Maple Grove, MN, 55311

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records